Synthesis of triazolotriazine derivatives as c-Met inhibitors

被引:6
|
作者
Guo, Yuting [1 ,3 ]
Peng, Xia [2 ]
Ji, Yinchun [2 ]
Zhang, Yitong [2 ,3 ]
Ding, Jian [2 ,3 ]
Zhan, Zhengsheng [1 ]
Ai, Jing [2 ,3 ]
Duan, Wenhu [1 ,3 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China
[3] Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China
基金
中国国家自然科学基金;
关键词
Receptor tyrosine kinase; c-Met; Triazolotriazine; SAR; Cellular potency; GROWTH-FACTOR RECEPTOR; KINASE INHIBITOR; HIGHLY POTENT; DISCOVERY; IDENTIFICATION; PROTOONCOGENE; CABOZANTINIB; METASTASIS; VOLITINIB; PATHWAY;
D O I
10.1007/s11030-020-10067-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Receptor tyrosine kinase c-Met is an important antitumor drug target. Triazolotriazine analogues2-10were prepared efficiently and evaluated the enzymatic and cellular c-Met activities. Brief structure-activity relationships of triazolotriazine core and CF2-quinoline part were investigated, leading to the discovery of compound8with nanomolar enzymatic c-Met activity, and subnanomolar MKN45 and EBC-1 cellular potencies. The proposed binding model of 8 and c-Met unraveled that two canonical hydrogen bonds and a pi-pi stacking interaction formed between the inhibitor and the ATP binding site of c-Met kinase domain, which accounted for its potent c-Met activities. [GRAPHICS] .
引用
收藏
页码:839 / 846
页数:8
相关论文
共 50 条
  • [41] MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors
    Jardim, Denis L. F.
    Gagliato, Debora de Melo
    Falchook, Gerald
    Zinner, Ralph
    Wheler, Jennifer J.
    Janku, Filip
    Subbiah, Vivek
    Piha-Paul, Sarina A.
    Fu, Siqing
    Tannir, Nizar
    Corn, Paul
    Tang, Chad
    Hess, Kenneth
    Roy-Chowdhuri, Sinchita
    Kurzrock, Razelle
    Meric-Bernstam, Funda
    Hong, David S.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (01) : E19 - E26
  • [42] Combination of chemotherapy and c-MET inhibitors has synergistic effects in c-MET overexpressing pancreatic cancer cells
    Moosavi, Fatemeh
    Firoozi, Roya
    Tavakkoli, Marjan
    Nazari, Somayeh
    Alipour, Alireza
    Firuzi, Omidreza
    BIOCHIMIE, 2025, 231 : 73 - 83
  • [43] Autocrine c-met/HGF HCC patient derived xenograft (PDX) models for evaluating c-met inhibitors
    Chen, Dawei
    Song, Xiaoming
    Call, Jie
    Chen, Taiping
    Chen, Yiyou
    Li, Henry Q. X.
    CANCER RESEARCH, 2012, 72
  • [44] Optimization techniques for novel c-Met kinase inhibitors
    Sun, Zhi-Gang
    Yang, Yong-An
    Zhang, Zhi-Gang
    Zhu, Hai-Liang
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (01) : 59 - 69
  • [45] Recent Patents on the Development of c-Met Kinase Inhibitors
    Xu, Xiangming
    Yao, Lei
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2020, 15 (03) : 228 - 238
  • [46] C-Met, a marker of resistance to EGFR inhibitors in NSCLC
    Engelman, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 22 - 22
  • [47] Design, Synthesis, and Biological Evaluation of 2-Substituted Aniline Pyrimidine Derivatives as Potent Dual Mer/c-Met Inhibitors
    Huang, Daowei
    Chen, Ying
    Yang, Jixia
    Zhao, Bingyang
    Wang, Shouying
    Chai, Tingting
    Cui, Jie
    Zhou, Xiaolei
    Shang, Zhenhua
    MOLECULES, 2024, 29 (02):
  • [48] Design and synthesis of 3,3′-biscoumarin-based c-Met inhibitors
    Xu, Jimin
    Ai, Jing
    Liu, Sheng
    Peng, Xia
    Yu, Linqian
    Geng, Meiyu
    Nan, Fajun
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2014, 12 (22) : 3721 - 3734
  • [49] MEDI 176-Design, synthesis, and biological evaluation of potent c-met inhibitors
    D'Angelo, Noel D.
    Bellon, Steve
    Booker, Shon K.
    Burgess, Teresa L.
    Dominguez, Celia
    Dussault, Isabelle
    Fellows, Ingrid
    Hungate, Randall W.
    Lee, Matthew
    Liu, Longbin
    Rainbeau, Elizabeth
    Reider, Paul J.
    Siegmund, Aaron
    Tasker, Andrew
    Xi, Ning
    Xu, Shimin
    Kim, Tae-Seong
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 235
  • [50] Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy) quinoline derivatives as selective c-Met inhibitors
    Wang, Xiaoqiang
    Jiang, Nan
    Zhao, Sijia
    Xi, Shuancheng
    Wang, Jiao
    Jing, Tongfei
    Zhang, Wenyu
    Guo, Ming
    Gong, Ping
    Zhai, Xin
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (03) : 886 - 896